Amgen (Nasdaq: AMGN) and Cytokinetics Incorporated (Nasdaq: CYTK) announced the presentation of data from the expansion phase of COSMIC-HF (Chronic ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Amgen (AMGN) Announces ABP 501 Phase 3 Met Primary Endpoint in RA vs AdalimumabNovember 9, 2015 5:31 PM Cytokinetics (CYTK) and Amgen Inc. (AMGN) Announce COSMIC-HF Data; Roth Capital Raises Price Target to $22 November 9, 2015 7:32 AM Amgen and Cytokinetics Announce Late-Breaking Presentation of COSMIC-HF Trial at AHA Scientific Sessions 2015November 8, 2015 3:45 PM Amgen And Cytokinetics Announce Late-Breaking Presentation Of COSMIC-HF Trial At AHA Scientific Sessions 2015November 8, 2015 3:45 PM